Stockreport

IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study [Yahoo! Finance]

Immuneering Corporation - Class A  (IMRX) 
PDF Immuneering Corporation IMRX soared 41.3% on Friday after it reported promising early response data from the first five patients of an ongoing early to mid-stage study [Read more]